PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan

References

• Adamson PC. 1996. All-trans-retinoic acid pharmacology and its impact on the treatment of acute promyelocytic leukemia. Oncologist. 1:305–314.
   PubMedGoogle Scholar
• Akimoto K, Kawai A, Ohya K. 1994. Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT-11 and SN-38, in aqueous solution. Chem Pharm Bull. 42:2135–2138.
   Web of Science ®Google Scholar
• Allen TM, Cullis PR. 2004. Drug delivery systems: entering the mainstream. Science. 303:1818–1822.
   PubMed Web of Science ®Google Scholar
• Berry DC, Levi L, Noy N. 2014. Holo-retinol-binding protein and its receptor STRA6 drive oncogenic transformation. Cancer Res. 74:6341–6351.
   PubMed Web of Science ®Google Scholar
• Boddu Sai HS, Vaishya R, Jwala J, Vadlapudi A, Pal D, Mitra AK. 2012. Preparation and characterization of folate conjugated nanoparticles of doxorubicin using PLGA-PEG-FOL Polymer. Med Chem. 2:068–075.
   Google Scholar
• Boige V, Taïeb J, Hebbar M, Malka D, Debaere T, Hannoun L, Magherini E, Mignard D, Poynard T, Ducreux M. 2006. Irinotecan as first-line chemotherapy in patients with advanced hepatocellular carcinoma: a multicenter phase II study with dose adjustment according to baseline serum bilirubin level. Eur J Cancer. 42:456–459.
   PubMed Web of Science ®Google Scholar
• Brtko J, Thalhamer J. 2003. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. CPD. 9:2067–2077.
   Google Scholar
• Bukhari MH, Qureshi SS, Niazi S, Asef M, Naheed M, Khan SA, Chaudhry NA, Tayyab M, Hasan M. 2007. Chemotherapeutic/chemopreventive role of retinoids in chemically induced skin carcinogenesis in albino mice. Int J Dermatol. 46:1160–1165.
   PubMed Web of Science ®Google Scholar
• Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. 2007. Formulation of functionalized PLGA–PEG nanoparticles for in-vivo targeted drug delivery. Biomaterials. 28:869–876.
   PubMed Web of Science ®Google Scholar
• Costa P, Lobo JMS. 2001. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 13:123–133.
   PubMed Web of Science ®Google Scholar
• de The H, Chomienne C, Lanotte M, Degos L, Dejean A. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature. 347:558–561.
   PubMed Web of Science ®Google Scholar
• Ebrahimnejad P, Dinarvand R, Sajadi A, Jaafari MR, Nomani AR, Azizi E, Rad-Malekshahi M, Atyabi F. 2010. Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. Nanomedicine. 6:478–485.
   PubMed Web of Science ®Google Scholar
• Emami J, Pourmashhadi A, Sadeghi H, Varshosaz J, Hamishehkar H. 2015. Formulation and optimization of celecoxib-loaded PLGA nanoparticles by the Taguchi design and their in vitro cytotoxicity for lung cancer therapy. Pharm Dev Technol. 20:791–800.
   PubMed Web of Science ®Google Scholar
• Emami J, Rezazade M, Varshosaz J, Tabbakhian M, Aslani A. 2012. Formulation of LDL targeted nanostructured lipid carrier loaded paclitaxel; a detailed of preparation, freeze drying condition, and in vitro cytotoxicity. J Nanomaterial. 2012:358782.
   Web of Science ®Google Scholar
• Emami J, Rezazadeh M, Rostami M, Hassanzadeh F, Sadeghi H, Mostafavi A, Minaiyan M, Lavasanifar A. 2015. Co-delivery of paclitaxel and α-tocopherol succinate by novel chitosan-based polymeric micelles for improving micellar stability and efficacious combination therapy. Drug Dev Ind Pharm. 41:1137–1147.
   PubMed Web of Science ®Google Scholar
• Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M, Dinarvand R. 2008. Folate-receptor- targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target. 16:415–423.
   PubMed Web of Science ®Google Scholar
• Fuchs C, Mitchell EP, Hoff PM. 2006. Irinotecan in the treatment of colorectal cancer. Cancer Treat Rev. 32:491–503.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. 2002. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 8:641–661.
   PubMed Web of Science ®Google Scholar
• Gershenson DM. 2002. Irinotecan in epithelial ovarian cancer. Oncology (Williston Park). 16:29–31.
   PubMed Web of Science ®Google Scholar
• Green MR, Harper M, Safa A, Sherman CA, Mushtaq CM, Bahadori H, Brescia FJ, Rocha Lima CM. 2000. Irinotecan in the management of patients with pancreatic cancer. Oncology (Williston Park). 14(12 Suppl 14):31–33.
   Web of Science ®Google Scholar
• Hami Z, Amini M, Ghazi-Khansari M, Rezayat SM, Gilani K. 2014. Doxorubicin-conjugated PLA-PEG-Folate based polymeric micelle for tumor-targeted delivery: synthesis and in vitro evaluation. DARU. 22:30.
   PubMed Web of Science ®Google Scholar
• Hami Z, Amini M, Ghazi-Khansari M, Rezayat SM, Gilani K. 2014. Doxorubicin-conjugated PLA-PEG-Folate based polymeric micelle for tumor-targeted delivery: synthesis and in vitro evaluation. DARU. 22:1–7.
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci. 95:4607–4612.
   PubMed Web of Science ®Google Scholar
• Hong WK, Sporn MB. 1997. Recent advances in chemoprevention of cancer. Science. 278:1073–1077.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Lihou MG, Liu LF. 1989. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:5077–5082.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Wu HY, Liu LF. 1988. Topoisomerases: novel therapeutic targets in cancer chemotherapy. Biochem Pharmacol. 37:1801–1802.
   PubMed Web of Science ®Google Scholar
• Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, Gu L, Wang Z. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:567–572.
   PubMed Web of Science ®Google Scholar
• Jindal N, Mehta SK. 2015. Nevirapine loaded poloxamer/pluronic P123 mixed micelles: optimization of formulation and in vitro evaluation. Colloid Surf B. 129:100–106.
   PubMed Web of Science ®Google Scholar
• Kaparissides C, Alexandridou S, Kotti K, Chaitidou S. 2006. Recent advances in novel drug delivery systems. J Nano Tech. 2:1–11.
   Google Scholar
• Kawaguchi R, Zhong M, Kassai M, Ter-Stepanian M, Sun H. 2015. Vitamin A transport mechanism of the multitransmembrane, cell-surface receptor STRA6. Membranes. 5:425–453.
   PubMed Web of Science ®Google Scholar
• Kim K, Kwon S, Hyung PJ, Chung H, Young JS. 2003. Physicochemical characteristics of self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid. Langmuir. 19:10188–10193.
   Web of Science ®Google Scholar
• Kudgus RA, Walden CA, McGovern RM, Reid JM, Robertson JD, Mukherjee P. 2014. Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting compound. Sci Rep. 4:5669.
   PubMed Web of Science ®Google Scholar
• Kwon GS. 2003. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carrier Syst. 20:357–403.
   PubMed Web of Science ®Google Scholar
• Li W, Zhana P, Clercqb ED, Loua H, Liua X. 2013. Current drug research on PEGylation with small molecular agents. Prog Pol Sci. 38:421–444.
   Web of Science ®Google Scholar
• Mahalwara A, Sharmaa A, Sahub R. 2012. Evaluation of receptor mediated endocytosis on cellular internalization: a comparative study of pegylated nanoparticles and folate anchored pegylated nanoparticles on mda-mb-231 cells. Int J Biol Pharm Res. 3:431–443.
   Google Scholar
• Miller WH Jr. 1998. The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer. Cancer. 83:1471–1482.
   PubMed Web of Science ®Google Scholar
• Mishra P, Nayak B, Dey RK. 2016. PEGylation in anticancer therapy: an overview. Asian J Pharm Sci. 11:337–348.
   Web of Science ®Google Scholar
• Nagarwal RC, Kant S, Singh PN, Maiti P, Pandit JK. 2009. Polymeric nanoparticulate system: a potential approach for ocular drug delivery. J Control Release. 136:2–13.
   PubMed Web of Science ®Google Scholar
• Nason-Burchenal K, Dmitrovsky E. 1999. The retinoids: cancer therapy and prevention mechanisms. In: Nau H, Blaner W, editors. Retinoids, the biochemical and molecular basis of vitamin A and retinoid action (Handbook of Experimental Pharmacology). Vol. 139, Berlin: Springer; p. 301–322.
   Google Scholar
• Ojima I. 2008. Guided molecular missiles for tumor-targeting chemotherapy: case studies using the 2nd-generation taxoids as warheads. ACC Chem Res. 41:108–119.
   PubMed Web of Science ®Google Scholar
• Peppas NA, Sahlin JJ. 1989. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm. 57:169–172.
   Web of Science ®Google Scholar
• Potmesil M. 1994. Camptothecins: from bench research to hospital wards. Cancer Res. 54:1431–1439.
   PubMed Web of Science ®Google Scholar
• Ramesh M, Ahlawat P, Srinivas NR. 2010. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 24:104–123.
   PubMed Web of Science ®Google Scholar
• Rezazadeh M, Emami J, Hasanzadeh F, Sadeghi H, Minaiyan M, Mostafavi A, Rostami M, Lavasanifar A. 2016. In vivo pharmacokinetics, biodistribution and anti-tumor effect of paclitaxel-loaded targeted chitosan-based polymeric micelle. Drug Deliv. 23:1707–1717.
   PubMed Web of Science ®Google Scholar
• Ritger PL, Peppas NA. 1987. A simple equation for description of solute release I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release. 5:23–36.
   Google Scholar
• Robert J, Rivory L. 1998. Pharmacology of irinotecan. Drugs Today. 34:777–803.
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Hirotsu S, Hirota S. 1999. Effective irinotecan (CPT-11)-containing liposomes: intraliposomal conversion to the active metabolite SN-38. Jpn J Cancer Res. 90:226–232.
   PubMedGoogle Scholar
• Saxena V, Naguib Y, Delwar Hussain M. 2012. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-aag) loaded polymeric nanoparticles for breast cancer. Colloid Surf B. 94:274–280.
   PubMed Web of Science ®Google Scholar
• Sharma S, Sharma MC. 2016. Development and validation of Spectrophotometric method and TLC densitometric determination of irinotecan HCl in pharmaceutical dosage forms. Arab J Chem. 9:S1368–S1372.
   Web of Science ®Google Scholar
• Siddikuzzaman GC, Berlin Grace VM. 2011. All-trans retinoic acid and cancer. Immunopharmacol Immunotoxicol. 33:241–249.
   PubMed Web of Science ®Google Scholar
• Sun R, Liu Y, Li SY, Shen S, Du XJ, Xu CF, Cao ZT, Bao Y, Zhu YH, Li YP, et al. 2015. Co-delivery of all-trans-retinoic acid and doxorubicin for cancer therapy with synergistic inhibition of cancer stem cells. Biomaterials. 37:405–414.
   PubMed Web of Science ®Google Scholar
• Szeto W, Jiang W, Tice DA, Rubinfeld B, Hollingshead PG, Fong SE, Dugger DL, Pham T, Yansura DG, Wong TA, et al. 2001. Overexpression of the retinoic acid-responsive gene STRA6 in human cancers and its synergistic induction by wnt-1 and retinoic acid. Cancer Res. 61:4197–4205.
   PubMed Web of Science ®Google Scholar
• Tochilin VP. 2001. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 56:337–346.
   Google Scholar
• Torchilin VP. 2010. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol. 197:3–53.
   PubMedGoogle Scholar
• Tortorella S, Karagiannis TC. 2014. Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol. 247:291–307.
   PubMed Web of Science ®Google Scholar
• Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. 2001. Irinotecan in the treatment of colorectal cancer: clinical overview. JCO. 19:1501–1518.
   PubMed Web of Science ®Google Scholar
• Varshosaz J, Hassanzadeh F, Sadeghi H, Ghelich Khan Z, Rostami M. 2013. Retinoic acid decorated albumin-chitosan nanoparticle for targeted delivery of doxorubicin hydrochloride in hepatocellular carcinoma. J Nanomater. 2013:254127.
   Google Scholar
• Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS. 2009. Experience with irinotecan for the treatment of malignant glioma. Neuro-oncology. 11:80–91.
   PubMed Web of Science ®Google Scholar
• Wamoto T. 2013. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effect of approved drugs. Biol Pharm Bull. 36:715–718.
   PubMed Web of Science ®Google Scholar
• Wang F, Chen Y, Zhang D, Zhang Q, Zheng D, Hao L, Liu Y, Duan C, Jia L, Liu G. 2012. Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid-O-carboxymethylated chitosan–folic acid micelles. Int J Nanomed. 7:325–337.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shao J, Li L, Peng X, Chen M, Li G, Yan H, Yang B, Luo P, He Q. 2016. All-trans retinoic acid synergizes with topotecan to suppress AML cells via promoting RARα-mediated DNA damage. BMC Cancer. 16:2.
   PubMed Web of Science ®Google Scholar
• Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Needham D, Viglianti BL, Dewhirst MW. 2010. Comparative effects of thermo sensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumors. Int J Hyperthermia. 26:485–498.
   PubMed Web of Science ®Google Scholar
• Yoo HS, Park TG. 2004. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Release. 96:273–283.
   PubMed Web of Science ®Google Scholar
• Zhang L, Cao DY, Wang J, Xiang B, Dun JN. 2013. PEG-coated irinotecan cationic liposomes improve the therapeutic efficacy of breast cancer in animals. Eur Rev Med Pharmocol Sci. 17:3347–3361.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Yao J. 2012. Preparation of irinotecan-loaded folate-targeted liposome for tumor targeting delivery and its antitumor activity. AAPS Pharm Sci Tech. 13:802–810.
   PubMed Web of Science ®Google Scholar
• Zhou J, Romero G, Rojas E, Moya S, Ma L, Gao C. 2010. Folic acid modified poly(lactide-co-Glycolide) nanoparticles, layer-by-layer surface engineered for targeted delivery. Macromol Chem Phys. 211:404–411.
   Web of Science ®Google Scholar
• Zwicke GL, Mansoori GA, Jeffery CJ. 2012. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 3:18496.
   PubMedGoogle Scholar